AMZN

210.15

+2.4%↑

TSLA

380.77

+3.53%↑

330.77

+3.02%↑

210.24

+2.62%↑

MCD

308.25

-0.38%↓

AMZN

210.15

+2.4%↑

TSLA

380.77

+3.53%↑

330.77

+3.02%↑

210.24

+2.62%↑

MCD

308.25

-0.38%↓

AMZN

210.15

+2.4%↑

TSLA

380.77

+3.53%↑

330.77

+3.02%↑

210.24

+2.62%↑

MCD

308.25

-0.38%↓

AMZN

210.15

+2.4%↑

TSLA

380.77

+3.53%↑

330.77

+3.02%↑

210.24

+2.62%↑

MCD

308.25

-0.38%↓

AMZN

210.15

+2.4%↑

TSLA

380.77

+3.53%↑

330.77

+3.02%↑

210.24

+2.62%↑

MCD

308.25

-0.38%↓

Home・Akciju saraksts・Hovnanian Enterprises Inc

Hovnanian Enterprises Inc

Slēgts

108.38 4.96

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

103.26

Max

110.06

Galvenie mērījumi
By Trading Economics
Ienākumi	22M 21M
Pārdošana	-186M 632M
P/E Sektora vidējais	16.638 33.36
Peļņas marža	3.301
Darbinieki	1,891
EBITDA	33M 44M

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 19. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-98M 639M
Iepriekšējā atvēršanas cena	103.42
Iepriekšējā slēgšanas cena	108.38

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bullish Evidence

98.09 / 104.42 Atbalsts un pretestība

Hovnanian Enterprises Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 23. marts 23:47 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

2026. g. 23. marts 22:55 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

2026. g. 23. marts 21:51 UTC

Iegādes, apvienošanās, pārņemšana

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

2026. g. 23. marts 23:59 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 23. marts 23:59 UTC

Tirgus saruna

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

2026. g. 23. marts 23:50 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

2026. g. 23. marts 23:37 UTC

Tirgus saruna

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

2026. g. 23. marts 22:42 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Equities Roundup: Market Talk

2026. g. 23. marts 22:42 UTC

Tirgus saruna

Galvenie ziņu notikumi

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

2026. g. 23. marts 22:40 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

2026. g. 23. marts 22:23 UTC

Tirgus saruna

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

2026. g. 23. marts 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

2026. g. 23. marts 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

2026. g. 23. marts 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

2026. g. 23. marts 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

2026. g. 23. marts 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

2026. g. 23. marts 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

2026. g. 23. marts 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

2026. g. 23. marts 22:18 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

2026. g. 23. marts 22:15 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

2026. g. 23. marts 22:08 UTC

Tirgus saruna

Ebos Needs to Reset Its Gearing Targets -- Market Talk

2026. g. 23. marts 21:42 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 23. marts 21:42 UTC

Tirgus saruna

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

2026. g. 23. marts 21:10 UTC

Galvenie ziņu notikumi

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

2026. g. 23. marts 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 23. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 23. marts 20:50 UTC

Tirgus saruna

Peļņas

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Hovnanian Enterprises Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Hovnanian Enterprises Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

98.09 / 104.42Atbalsts un pretestība

All events are bullish.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Hovnanian Enterprises Inc

Hovnanian Enterprises, Inc., through its subsidiaries, designs, constructs, markets, and sells residential homes in the United States. It offers single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes with amenities, such as clubhouses, swimming pools, tennis courts, tot lots, and open areas. The company markets and builds homes for first-time buyers, first-time and second-time move-up buyers, luxury buyers, active lifestyle buyers, and empty nesters. It also provides mortgage loans, title insurance, and homeowner's insurance services. The company was founded in 1959 and is headquartered in Matawan, New Jersey.